Literature DB >> 7820043

The Scripps Clinic experience with 2-chlorodeoxyadenosine in the treatment of hairy cell leukemia.

L D Piro1, D J Ellison, A Saven.   

Abstract

Follow-up data is now available on 144 patients with hairy cell leukemia treated with 2-chlorodeoxyadenosine (2-CdA) at the Scripps Clinic. Of 144 patients followed for a median of 14.2 months, 123 (85%) obtained complete responses, 17 (12%) partial responses, 3 (2%) did not respond and 1 patients was unevaluable. So far, only 4 patients have relapsed at a median of 36 months. Fever was the major toxicity occurring in 43% of patients. Five patients resistant (3 patients) or intolerant (2 patients) to 2'-deoxycoformycin were also treated. Of these 5 patients, 4 obtained complete responses, including 2 patients resistant to 2'-deoxycoformycin, and 1 patient a partial response, suggesting a possible lack of cross-resistance between 2'-deoxycoformycin and 2-CdA in hairy-cell leukemia. More than 200 patients have been treated with 2-CdA worldwide with 82% obtaining complete remission and 12% partial remissions. Serial peripheral blood immunophenotypic analyses have documented the absence of circulating hairy cells. When bone marrow biopsies were examined using sensitive immunohistochemical staining techniques, residual hairy cells were detected in 25-50% of morphologic complete responders. Patients will need to be observed longitudinally to determine if this staining is predictive of relapse. A double-blind, placebo-controlled study of pentoxifylline, a modulator of tumor necrosis factor-alpha and other cytokines, was performed in 2-CdA-treated hairy cell leukemia patients to determine whether the incidence of neutropenic fever would be reduced. Although pentoxifylline resulted in less febrile, hospital and antibiotic therapy days than placebo, only the number of days in the hospitalized patients achieved statistical significance. 2-CdA is emerging as the treatment of choice for hairy cell leukemia given the high percentage of long-lasting, complete responses that follow a single course of therapy.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7820043

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  4 in total

1.  Phase II clinical study of cladribine in the treatment of hairy cell leukemia.

Authors:  Takashi Machii; Takaaki Chou; Muneou Suzuki; Yokiko Ohe; Shuichi Katagiri; E Kiyoshi Kitano; Kiyoshi Kitano; Yoshihide Fujiyama; Tooru Izumi; Chihiro Shimazaki; Koji Nanba; Yasuo Ohashi; Teruo Kitani
Journal:  Int J Hematol       Date:  2005-10       Impact factor: 2.490

Review 2.  The clinical pharmacokinetics of cladribine.

Authors:  J Liliemark
Journal:  Clin Pharmacokinet       Date:  1997-02       Impact factor: 6.447

Review 3.  The optimal management of hairy cell leukaemia.

Authors:  R Gollard; T C Lee; L D Piro; A Saven
Journal:  Drugs       Date:  1995-06       Impact factor: 9.546

4.  VH4-34+ hairy cell leukemia, a new variant with poor prognosis despite standard therapy.

Authors:  Evgeny Arons; Tara Suntum; Maryalice Stetler-Stevenson; Robert J Kreitman
Journal:  Blood       Date:  2009-09-10       Impact factor: 22.113

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.